Sido Muncul Optimistic Performance Grows 10 Percent In 2025

JAKARTA - PT Industri Jamu Dan Farmasi Sido Muncul Tbk (SIDO), the largest herbal medicine producer in Indonesia, will expand the distribution network, strengthen market penetration, and accelerate product innovation in 2025.

"The company is optimistic that it will achieve 10 percent growth in sales and net profit, by utilizing strong brand equity, solid financial position, and commitment to innovation," explained the company's statement quoted from the information disclosure page of the Indonesia Stock Exchange, Saturday, March 8.

Furthermore, SIDO remains in a strong position to seize opportunities in the growing consumer herbal market and health, to create long-term value for shareholders.

For information, SIDO posted solid performance throughout 2024, driven by volume growth, sustainable market expansion, and product innovation, as well as strengthening its position as the leader of the herbal industry in Indonesia, amid macroeconomic challenges.

Quoted from the disclosure of information on the Indonesia Stock Exchange (IDX) website, Friday, March 7, the company recorded full year 2024 net sales of IDR 3.92 trillion, an increase of 10 percent on an annual basis, supported by strong performance in all segments: Herbal & Suplemen (+6 percent YoY), Food & Beverage (+18 percent YoY) and Pharmacy (+10 percent YoY).

Gross profit margins increased to 59 percent, reflecting operational efficiency, economic scale, and lower food & beverage segment raw material prices. Operating profit jumped 24 percent to IDR 1.47 trillion, driven by higher sales volume and effective cost management.

Net profit also grew 23 percent to IDR 1.17 trillion, with a net profit margin of 30 percent, reflecting cost efficiency and operational leverage.

The SIDO balance sheet remains strong, with a debt-free position and a healthy cash balance of IDR 856 billion, strengthening the company's resilience and supporting future expansion.

International sales continue to show a positive trend, contributing 7 percent of total revenue, with a growth of 36 percent on an annual basis. The strategic expansion to Southeast Asia and Africa further strengthens multi-channel penetration, a more in-depth brand presence, and increased consumer adoption.

SIDO's international sales contribution has more than tripled since FY20, indicating a successful and sustainable global expansion strategy. Product innovation remains the main pillar of SIDO's growth. In 2024, the company launched ten new products, including Tolak Angin Liquid for Cough, various Sido Muncul Natural Supplements, as well as new variants of F&B, in accordance with consumer health trends.